Companies / Biogen
Biogen
CompanyBiogen is an American multinational biotechnology company headquartered in Cambridge, Massachusetts, focused on treatments for neurological diseases. Founded in 1978, the company markets therapies across neurology indications and is publicly traded on Nasdaq.
- Trials
- 508
- Recruiting
- 18
- Completed
- 356
- With results
- 126
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Approved for marketing | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | — | 2 | — | — | — | — | 2 |
| Phase 1 | 4 | — | — | 2 | 139 | 17 | 2 | — | — | 164 |
| Phase 1/2 | — | — | — | — | 7 | 5 | 1 | — | — | 13 |
| Phase 2 | 2 | — | — | 1 | 59 | 23 | 7 | — | — | 92 |
| Phase 2/3 | — | — | — | 1 | 2 | — | — | — | — | 3 |
| Phase 3 | 6 | 1 | 3 | 6 | 47 | 26 | 3 | — | — | 92 |
| Phase 4 | — | — | — | 1 | 29 | 6 | 6 | — | — | 42 |
| Not applicable | — | — | — | — | 3 | — | — | — | — | 3 |
| Unknown | 6 | — | — | 6 | 68 | 13 | 1 | 1 | 2 | 97 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Multiple Sclerosis | 1 | 10 | — | 13 | 1 | 25 | 19 | 1 | 46 | 116 |
| Multiple Sclerosis, Relapsing-Remitting | — | 4 | — | 9 | — | 25 | 21 | — | 19 | 78 |
| Muscular Atrophy, Spinal | — | 5 | 1 | 3 | — | 9 | 1 | 2 | 6 | 27 |
| Arthritis, Rheumatoid | — | 1 | — | 10 | — | — | — | — | 5 | 16 |
| Alzheimer Disease | — | 5 | — | 2 | — | 4 | — | — | 1 | 12 |
| Recurrence | — | 3 | 1 | — | — | 7 | — | — | 1 | 12 |
| Crohn Disease | — | — | — | 2 | — | 3 | 2 | — | 4 | 11 |
| Parkinson Disease | — | 3 | — | 6 | — | 1 | — | — | — | 10 |
| Renal Insufficiency, Chronic | — | 3 | — | 4 | — | 2 | — | — | — | 9 |
| Amyotrophic Lateral Sclerosis | — | 3 | 1 | — | — | 1 | 1 | — | 2 | 8 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Biogen | 508 | 95 |
Frequent collaborators
| # | Collaborator | Trials |
|---|---|---|
| 1 | Elan Pharmaceuticals | 25 |
| 2 | AbbVie | 14 |
| 3 | Denali Therapeutics Inc. | 4 |
| 4 | Acorda Therapeutics | 2 |
| 5 | Alkermes, Inc. | 2 |
| 6 | Celerion | 2 |
| 7 | Ionis Pharmaceuticals, Inc. | 2 |
| 8 | Q2 Solutions | 2 |
| 9 | Alcyone Therapeutics, Inc | 1 |
| 10 | Altasciences Company Inc. | 1 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Natalizumab | 59 |
| 2 | Dimethyl Fumarate | 48 |
| 3 | Interferon beta-1a | 37 |
| 4 | bardoxolone methyl | 24 |
| 5 | vixotrigine | 20 |
| 6 | omaveloxolone | 19 |
| 7 | nusinersen | 18 |
| 8 | peginterferon beta-1a | 16 |
| 9 | zuranolone | 16 |
| 10 | PF-04958242 | 14 |
Evidence
- Results reported
- 35.4%126 of 356 completed
- Published
- 3.9%14 of 356 completed
- Primary endpoint met
- 43.8%53 of 121 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 74
- Median duration
- 21months
- Countries
- 70
- Study sites
- 6398
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 16
- Phase 1
- 36
- Phase 1/2
- 37
- Phase 2
- 97
- Phase 2/3
- 187
- Phase 3
- 221
- Phase 4
- 70
- Not applicable
- 93
- Unknown
- 289
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Boston | United States | 93 |
| 2 | Dallas | United States | 88 |
| 3 | New York | United States | 82 |
| 4 | St Louis | United States | 72 |
| 5 | London | United Kingdom | 69 |
| 6 | Philadelphia | United States | 69 |
| 7 | Atlanta | United States | 68 |
| 8 | Houston | United States | 68 |
| 9 | Los Angeles | United States | 68 |
| 10 | Chicago | United States | 60 |
Terminations
- Terminated
- 90
- Withdrawn
- 20
- Stopped for recruitment
- 1.8%9 of 508 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT02428218 Withdrawn | Withdrawn | Feasibility | 2027-01-31 |
| NCT03637387 Withdrawn | Withdrawn | Sponsor Decision | 2026-09-29 |
| NCT03070132 Withdrawn | Withdrawn | Sponsor Decision | 2026-08-21 |
| NCT05764122 Withdrawn | Withdrawn | Sponsor decision | 2025-07-07 |
| NCT04079088 Withdrawn | Withdrawn | Decision to discontinue BIIB061 program was based on lack of stronger preclinical effects of BIIB061 on remyelination relative to opicinumab, that showed limited clinical efficacy in phase 2 clinical studies. This was not related to safety concerns. | 2024-09-18 |
| NCT04494256 Terminated | Terminated | Sponsor's decision | 2024-08-13 |
| NCT05310071 Terminated | Terminated | Sponsor's Decision | 2024-08-12 |
| NCT05701423 Terminated | Terminated | Due to low enrolment the sponsor decided to terminate the study | 2024-07-31 |
| NCT04241068 Terminated | Terminated | Sponsor's Decision | 2024-07-22 |
| NCT05265728 Terminated | Terminated | Due to sponsor decision, not for efficacy or safety reasons. | 2024-05-27 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: